Patents by Inventor Joshua Hummel

Joshua Hummel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bicyclic pyrazolyl amines as CDK2 inhibitors
    Patent number: 11981671
    Abstract: The present application provides bicyclic amines of Formula (I): or a pharmaceutically acceptable salt thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Grant
    Filed: June 21, 2022
    Date of Patent: May 14, 2024
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, Jingwei Li, Ding-Quan Qian, Liangxing Wu
  • Bicyclic amines as CDK2 inhibitors
    Patent number: 11976073
    Abstract: The present application provides bicyclic amines of Formula (I): and their pharmaceutically acceptable salts thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: May 7, 2024
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, David M. Burns, Ding-Quan Qian, Xiaozhao Wang
  • TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS
    Publication number: 20240083898
    Abstract: The present application provides tricyclic triazolo compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: August 11, 2023
    Publication date: March 14, 2024
    Inventors: Joshua Hummel, Ding-Quan Qian, Xiaozhao Wang, Meizhong Xu
  • TETRACYCLIC COMPOUNDS AS DGK INHIBITORS
    Publication number: 20240034734
    Abstract: The present application provides tetracyclic compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: July 17, 2023
    Publication date: February 1, 2024
    Inventors: Joshua Hummel, Shicheng Shi, Xiaozhao Wang
  • TETRACYCLIC COMPOUNDS AS DGK INHIBITORS
    Publication number: 20240025900
    Abstract: The present application provides tetracyclic compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: July 17, 2023
    Publication date: January 25, 2024
    Inventors: Joshua Hummel, Shicheng Shi, Xiaozhao Wang
  • Benzothiazole compounds and uses thereof
    Patent number: 11866426
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: January 9, 2024
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, Oleg Vechorkin, Alexander Sokolsky, Qinda Ye, Kai Liu, Wenqing Yao
  • TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS
    Publication number: 20230399342
    Abstract: The present application provides tricyclic triazolo compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: June 7, 2023
    Publication date: December 14, 2023
    Inventors: Joshua Hummel, Liana Hie, Jacob J. Lacharity, Xiaolei Li, Sharada Manns, Ding-Quan Qian, Xiaozhao Wang, Bo Wei, Meizhong Xu
  • BICYCLIC AMINES AS CDK2 INHIBITORS
    Publication number: 20230192706
    Abstract: The present application provides bicyclic amines of Formula (I): and their pharmaceutically acceptable salts thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: December 9, 2022
    Publication date: June 22, 2023
    Inventors: Joshua Hummel, David M. Burns, Ding-Quan Qian, Xiaozhao Wang, Ming Xiang, Jingwei Li
  • BICYCLIC AMINES AS CDK2 INHIBITORS
    Publication number: 20230183250
    Abstract: The present application provides bicyclic amines of Formula (I): and their pharmaceutically acceptable salts thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: December 9, 2022
    Publication date: June 15, 2023
    Inventors: Joshua Hummel, David M. Burns, Ding-Quan Qian, Xiaozhao Wang
  • BICYCLIC PYRAZOLYL AMINES AS CDK2 INHIBITORS
    Publication number: 20230002376
    Abstract: The present application provides bicyclic amines of Formula (I): or a pharmaceutically acceptable salt thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: June 21, 2022
    Publication date: January 5, 2023
    Inventors: Joshua Hummel, Jingwei Li, Ding-Quan Qian, Liangxing Wu
  • Pyrazolopyrimidine compounds and uses thereof
    Patent number: 11542265
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: January 3, 2023
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Kai Liu, Jun Pan, Alexander Sokolsky, Hai Fen Ye, Qinda Ye, Wenqing Yao, Joshua Hummel
  • PYRAZOLYL BICYCLIC AMINES AS CDK2 INHIBITORS
    Publication number: 20220340579
    Abstract: The present application provides pyrazolyl bicyclic amines of Formula (I): and their pharmaceutically acceptable salts thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: April 12, 2022
    Publication date: October 27, 2022
    Inventors: Joshua Hummel, David M. Burns, Liangxing Wu, Wenqing Yao
  • Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
    Patent number: 11472791
    Abstract: The present application provides pyrazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: October 18, 2022
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, Jingwei Li, Zhenwu Li, Ding-Quan Qian, Liangxing Wu, Kaijiong Xiao, Meizhong Xu, Jeffrey C. Yang, Wenqing Yao, Fenglei Zhang, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
  • Benzimidazole and indole compounds and uses thereof
    Patent number: 11299473
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: April 12, 2022
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, Minh Nguyen, Alexander Sokolsky, Oleg Vechorkin, Qinda Ye, Wenqing Yao
  • PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20210371425
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Application
    Filed: April 23, 2021
    Publication date: December 2, 2021
    Inventors: Oleg Vechorkin, Kai Liu, Jun Pan, Alexander Sokolsky, Hai Fen Ye, Qinda Ye, Wenqing Yao, Joshua Hummel
  • BENZOTHIAZOLE COMPOUNDS AND USES THEREOF
    Publication number: 20210171518
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Application
    Filed: November 16, 2020
    Publication date: June 10, 2021
    Inventors: Joshua Hummel, Oleg Vechorkin, Alexander Sokolsky, Qinda Ye, Kai Liu, Wenqing Yao
  • Pyrazolopyrimidine compounds and uses thereof
    Patent number: 11014929
    Abstract: Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt thereof. Also provided are methods of using the compounds of Formula (I) for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: May 25, 2021
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Kai Liu, Jun Pan, Alexander Sokolsky, Hai Fen Ye, Qinda Ye, Wenqing Yao, Joshua Hummel
  • BICYCLIC AMINES AS CDK2 INHIBITORS
    Publication number: 20210107901
    Abstract: The present application provides bicyclic amines that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: October 9, 2020
    Publication date: April 15, 2021
    Inventors: Yingda Ye, Zhenwu Li, Ding-Quan Qian, Sarah Winterton, Kaijiong Xiao, Liangxing Wu, Wenqing Yao, Joshua Hummel, Meizhong Xu, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
  • Benzothiazole compounds and uses thereof
    Patent number: 10899755
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: January 26, 2021
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, Oleg Vechorkin, Alexander Sokolsky, Qinda Ye, Kai Liu, Wenqing Yao
  • PYRAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS
    Publication number: 20210017156
    Abstract: The present application provides pyrazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: March 4, 2020
    Publication date: January 21, 2021
    Inventors: Joshua Hummel, Jingwei Li, Zhenwu Li, Ding-Quan Qian, Liangxing Wu, Kaijiong Xiao, Meizhong Xu, Jeffrey C. Yang, Wenqing Yao, Fenglei Zhang, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo